Article
Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.
Journal of the National Cancer Institute - 1 Sept 2017
Hong Theodore S, Wo Jennifer Y, Borger Darrell R, Yeap Beow Y, McDonnell Erin I, Willers Henning, Blaszkowsky Lawrence S, Kwak Eunice L, Allen Jill N, Clark Jeffrey W, Tanguturi Shyam, Goyal Lipika, Murphy Janet E, Wolfgang John A, Drapek Lorraine C, Arellano Ronald S, Mamon Harvey J, Mullen John T, Tanabe Kenneth K, Ferrone Cristina R, Ryan David P, Iafrate A John, DeLaney Thomas F, Zhu Andrew X
Abstract excerpt
Background: We evaluated the efficacy and safety of risk-adapted, proton-based stereotactic body radiation therapy (SBRT) for liver metastases from solid tumors. Methods: This single-arm phase II single institutional study (NCT01239381) included patients with limited extrahepatic disease, 800 mL or greater of uninvolved liver, and no cirrhosis or Child-Pugh A, who had received proton-based SBRT to one to four...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.